Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.89 Analyst target: $6.28 Upside: 605.94%
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.